Long-Term Liabilities (Quarterly)

Long-Term Liabilities: The sum of all non-current liabilities.

BioCryst Pharmaceuticals, Inc. (BCRX) had Long-Term Liabilities of $644.08M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$159.40M
Net Income	$12.90M
Cost of Goods Sold	$2.19M
Gross Profit	$157.21M
Operating Expenses	$129.80M
Operating Income	$29.59M
Non-Operating Income/Expense	$-17.46M
Pre-Tax Income	$12.13M
Normalized Pre-Tax Income	$12.13M
Income after Taxes	$12.90M
Income from Continuous Operations	$12.90M
Consolidated Net Income/Loss	$12.90M
Normalized Income after Taxes	$12.90M
EBIT	$29.59M
EBITDA	$29.22M
Weighted-Average Shares Outstanding (Basic)	210.18M
Weighted-Average Shares Outstanding (Diluted)	219.88M
Earnings per Share (EPS) (Basic)	$0.06
Earnings per Share (EPS) (Diluted)	$0.06
Balance Sheet Financials
Current Assets	$355.68M
Property, Plant, and Equipment	$8.40M
Long-Term Assets	$90.74M
Total Assets	$446.42M
Current Liabilities	$190.24M
Long-Term Debt	$635.22M
Long-Term Liabilities	$644.08M
Total Liabilities	$834.31M
Common Equity	$-387.89M
Tangible Shareholders Equity	$-387.89M
Shareholders Equity	$-387.89M
Common Shares Outstanding	210.52M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$55.41M
Cash Flow from Investing Activities	$69.79M
Cash Flow from Financial Activities	$-131.97M
Beginning Cash	$-14.84M
End Cash	$-20.27M
Increase/Decrease in Cash	$-5.43M
Stock-Based Compensation	$61.27M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.87
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	2.57
Debt to Equity Ratio	-1.74
Gross Margin	98.63%
Operating Margin	18.56%
EBIT Margin	18.56%
EBITDA Margin	--
Pre-Tax Profit Margin	7.61%
Profit Margin	8.09%
Free Cash Flow	$53.74M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.36
Inventory Turnover	0.42
Receiveable Turnover	1.75
Days Sales in Receivables	51.57
Return on Equity	-3.33%
Return on Tangible Equity	-3.33%
Return on Assets	2.89%
Return on Investments	5.22%
Book Value Per Share	$-1.84
Free Cash Flow per Share	$0.24
Operating Cash Flow per Share	$0.25

Data from Zacks Investment Research, Inc.